Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 674.95

+3.1%

Nov 11 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (2976)	6/1/2020 6:18:01 PM
From: Miljenko Zuanic	of 3557

<Can hemophilia-A and -B markets support so many players? Is this a winner-take-all proposition?> Definitely, I am not one who can answer correctly here. I am one who think field is crowded (good multiple players already exist), and selective/specific targeting (liver) by CRISP may still be science fictions ! It is good that REGN is involved in the field and is trying, Intellia may be a good partner, but hem-A/B probably is off at this point. What is going on, for instance, with hearing Abs collaboration, or with viral-gene collaboration, or with...REGN talk only what is REGN doing! Sometimes, we need to hear colaborative efforts. They NEVER prised Sanofi for their ANY scientific contributions??!! It is ALL REGN!!!! Is it????

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next